2022
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA
Herrera A, Tracy S, Croft B, Opat S, Ray J, Lovejoy A, Musick L, Paulson J, Sehn L, Jiang Y. Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. Blood Advances 2022, 6: 1651-1660. PMID: 35086141, PMCID: PMC8941482, DOI: 10.1182/bloodadvances.2021006415.Peer-Reviewed Original ResearchConceptsCirculating tumor DNAInternational Prognostic IndexProgression-free survivalBaseline circulating tumour DNAEnd of treatmentOverall survivalR/R DLBCLComplete responseTumor DNARelapsed/refractory diffuse large B-cell lymphomaDiffuse large B-cell lymphomaMeasuring circulating tumor DNAShorter progression-free survivalLarge B-cell lymphomaHigh risk of progressionCirculating tumour DNA assaysLactate dehydrogenaseBaseline ctDNA levelRisk profile of patientsB-cell lymphomaRisk of relapseRisk of progressionSerum lactate dehydrogenaseProfile of patientsCtDNA assessment
2020
Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients By Measuring Circulating Tumor DNA
Herrera A, Tracy S, Croft B, Opat S, Ray J, Musick L, Paulson J, Sehn L, Jiang Y. Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients By Measuring Circulating Tumor DNA. Blood 2020, 136: 23-25. DOI: 10.1182/blood-2020-136645.Peer-Reviewed Original ResearchProgression-free survivalCirculating tumor DNACurrent equity holderInternational Prognostic IndexEntity's Board of DirectorsDetect circulating tumor DNABaseline ctDNA levelCtDNA levelsOverall survivalR/R DLBCLHazard ratioPrognostic factorsHigh riskTumor DNARefractory diffuse large B-cell lymphomaDiffuse large B-cell lymphoma patientsDiffuse large B-cell lymphomaMeasuring circulating tumor DNASource of germline DNACirculating tumor DNA levelsB-cell lymphoma patientsLarge B-cell lymphomaLactate dehydrogenaseEarly identification of patientsFirst-line setting
2019
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn L, Herrera A, Flowers C, Kamdar M, McMillan A, Hertzberg M, Assouline S, Kim T, Kim W, Ozcan M, Hirata J, Penuel E, Paulson J, Cheng J, Ku G, Matasar M. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal Of Clinical Oncology 2019, 38: 155-165. PMID: 31693429, PMCID: PMC7032881, DOI: 10.1200/jco.19.00172.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBiomarkers, TumorFemaleHumansImmunoconjugatesImmunohistochemistryLymphoma, Large B-Cell, DiffuseMaleMiddle AgedProgression-Free SurvivalSurvival RateConceptsProgression-free survivalLarge B-cell lymphomaPolatuzumab vedotinB-cell lymphomaCR rateOverall survivalPola-BRR/R DLBCLRefractory diffuse large B-cell lymphomaIRC-assessed progression-free survivalDiffuse large B-cell lymphomaB-cell receptor componentsSingle-arm cohortsDuration of responseCohort of patientsCox regression methodRisk of deathMedian OSSafety profileKaplan-MeierTreatment optionsB cellsPolatuzumabBendamustineDLBCL